Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 9/20 | 0.41 |
| ▸ | MERTK | Q12866 | 9/20 | 0.41 |
| ▸ | FLT3 | P36888 | 9/20 | 0.41 |
| ▸ | GAS6 | Q14393 | 8/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.39 |
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL722277 | 0.82 | CHUK (0.42) | TYRO3MERTKFLT3GAS6MAPK8 | |
| SCHEMBL3253565 | 0.82 | CHUK (0.42) | TYRO3MERTKFLT3GAS6MAPK8 | |
| SCHEMBL3250942 | 0.82 | CHUK (0.42) | TYRO3MERTKFLT3GAS6MAPK8 | |
| SCHEMBL3254416 | 0.79 | PTGDR2 (0.34) | — | |
| SCHEMBL3244787 | 0.77 | TP53 (0.38) | TYRO3MERTKFLT3GAS6ADORA1 | |
| SCHEMBL3244784 | 0.77 | TP53 (0.38) | TYRO3MERTKFLT3GAS6ADORA1 | |
| SCHEMBL3254180 | 0.74 | MERTK (0.34) | TYRO3MERTKFLT3GAS6MAPK3 | |
| SCHEMBL3254176 | 0.74 | MERTK (0.34) | TYRO3MERTKFLT3GAS6MAPK3 | |
| SCHEMBL3254181 | 0.74 | MERTK (0.34) | TYRO3MERTKFLT3GAS6MAPK3 | |
| SCHEMBL3245433 | 0.74 | ACACB (0.41) | TYRO3MERTKFLT3GAS6MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303495-B1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS INC (US) | 2010-05-26 | — | — | EP | claimed |
| US-7205297-B2 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | KRENITSKY PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | claimed |
| US-20040087789-A1 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | MIDCAP FUNDING III, LLC | 2004-05-06 | — | — | US | claimed |
| EP-1303495-A1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | Krenitsky Pharmaceuticals, Inc. (US) | 2003-04-23 | — | — | EP | claimed |
| WO-2002008205-A1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | claimed |
| EP-1303495-B1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS INC (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7205297-B2 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | KRENITSKY PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20040087789-A1 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | MIDCAP FUNDING III, LLC | 2004-05-06 | — | — | US | disclosed |
| EP-1303495-A1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | Krenitsky Pharmaceuticals, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002008205-A1 | SUBSTITUTED 5-ALKYNYL PYRIMIDINES HAVING NEUROTROPHIC ACTIVITY | KRENITSKY PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087789-A1 | Substituted 5-alkynyl pyrimidines having neurotrophic activity | BDNF, NTRK2, GAP43 | TYRO3 1454/4885MERTK 1581/4885FLT3 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.